IAM
AVDL

Iridian Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Iridian Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-85,800
Closed -$693K – 56
2021
Q4 		$693K Buy
+85,800
New +$784K 0.04% 64
2020
Q2 		– Sell
-159,100
Closed -$1.26M – 75
2020
Q1 		$1.26M Buy
+159,100
New +$1.22M 0.03% 55

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Iridian Asset Management's AVDL Position: Q1 2026 in Review

Iridian Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 247,086 shares — an estimated $5.32M sold.

Iridian Asset Management first reported a position in AVDL in Q2 2013 and held it in 31 quarters. The position peaked at $5.32M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Iridian Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Iridian Asset Management sold 247,086 Avadel Pharmaceuticals shares in Q1 2026, an estimated $5.32M.
  • Iridian Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 31 quarters.
  • Iridian Asset Management's Avadel Pharmaceuticals position peaked at $5.32M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Iridian Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.